Gene:
OPRM1
opioid receptor, mu 1

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for OPRM1

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs1799971 NC_000006.11:g.154360797A>G, NC_000006.12:g.154039662A>G, NG_021208.1:g.34162A>G, NM_000914.4:c.118A>G, NM_001008503.2:c.118A>G, NM_001008504.3:c.118A>G, NM_001008505.2:c.118A>G, NM_001145279.3:c.397A>G, NM_001145280.3:c.-11+28644A>G, NM_001145281.2:c.47+29103A>G, NM_001145282.2:c.118A>G, NM_001145283.2:c.118A>G, NM_001145284.3:c.118A>G, NM_001145285.2:c.118A>G, NM_001145286.2:c.118A>G, NM_001285522.1:c.118A>G, NM_001285523.1:c.118A>G, NM_001285524.1:c.397A>G, NP_000905.3:p.Asn40Asp, NP_001008503.2:p.Asn40Asp, NP_001008504.2:p.Asn40Asp, NP_001008505.2:p.Asn40Asp, NP_001138751.1:p.Asn133Asp, NP_001138754.1:p.Asn40Asp, NP_001138755.1:p.Asn40Asp, NP_001138756.1:p.Asn40Asp, NP_001138757.1:p.Asn40Asp, NP_001138758.1:p.Asn40Asp, NP_001272451.1:p.Asn40Asp, NP_001272452.1:p.Asn40Asp, NP_001272453.1:p.Asn133Asp, NR_104348.1:n.252A>G, NR_104349.1:n.252A>G, NR_104350.1:n.252A>G, NR_104351.1:n.252A>G, XM_005267002.1:c.304A>G, XM_006715497.2:c.304A>G, XM_011535849.1:c.397A>G, XP_005267059.1:p.Asn102Asp, XP_006715560.1:p.Asn102Asp, XP_011534151.1:p.Asn133Asp, XR_245534.1:n.304A>G, XR_245535.1:n.304A>G, XR_245536.1:n.304A>G, XR_245537.1:n.304A>G, rs17181017, rs52818856, rs61596185
A > G
SNP
N40D
No VIP available CA VA
rs2075572 NC_000006.11:g.154412004G>C, NC_000006.12:g.154090869G>C, NG_021208.1:g.85369G>C, NM_000914.4:c.644-83G>C, NM_001008503.2:c.644-83G>C, NM_001008504.3:c.644-83G>C, NM_001008505.2:c.644-83G>C, NM_001145279.3:c.923-83G>C, NM_001145280.3:c.344-83G>C, NM_001145281.2:c.401-83G>C, NM_001145282.2:c.644-83G>C, NM_001145283.2:c.644-83G>C, NM_001145284.3:c.644-83G>C, NM_001145285.2:c.644-83G>C, NM_001145286.2:c.644-83G>C, NM_001145287.2:c.344-83G>C, NM_001285522.1:c.291-27814G>C, NM_001285523.1:c.644-83G>C, NM_001285524.1:c.923-83G>C, NM_001285526.1:c.344-83G>C, NM_001285527.1:c.344-83G>C, NM_001285528.1:c.344-83G>C, NR_104348.1:n.778-83G>C, NR_104349.1:n.778-83G>C, NR_104350.1:n.425-83G>C, NR_104351.1:n.778-83G>C, XM_005267002.1:c.830-83G>C, XM_005267003.1:c.344-83G>C, XM_011535849.1:c.923-83G>C, XM_011535850.1:c.437-83G>C, XM_011535851.1:c.344-83G>C, XM_011535852.1:c.344-83G>C, XM_011535853.1:c.344-83G>C, XM_011535854.1:c.344-83G>C, XM_011535855.1:c.344-83G>C, XM_011535856.1:c.344-83G>C, XM_011535857.1:c.344-83G>C, XM_011535858.1:c.344-83G>C, XM_011535859.1:c.344-83G>C, XM_011535860.1:c.344-83G>C, XM_011535861.1:c.344-83G>C, XM_011535862.1:c.344-83G>C, XR_245534.1:n.830-83G>C, XR_245535.1:n.830-83G>C, XR_245536.1:n.830-83G>C, XR_245537.1:n.477-83G>C, rs17174815, rs17210094, rs56680128
G > C
SNP
No VIP available CA VA
rs2281617 NC_000006.11:g.154487421C>T, NC_000006.12:g.154166286C>T, NG_021208.1:g.160786C>T, NM_001008503.2:c.1164+74814C>T, NM_001130699.1:c.1104+1634G>A, NM_001130700.1:c.1104+1634G>A, NM_015553.2:c.1101+1634G>A, XM_005266919.1:c.1104+1634G>A, XM_005266919.3:c.1104+1634G>A, XM_005266920.1:c.1104+1634G>A, XM_005266920.3:c.1104+1634G>A, XM_005266921.1:c.1104+1634G>A, XM_005266921.3:c.1104+1634G>A, XM_005266922.1:c.1104+1634G>A, XM_005266922.3:c.1104+1634G>A, XM_005266923.1:c.1101+1634G>A, XM_005266923.2:c.1101+1634G>A, XM_011535739.1:c.1104+1634G>A, XM_011535740.1:c.1104+1634G>A, XM_011535741.1:c.1104+1634G>A, XM_011535742.1:c.1101+1634G>A, XM_011535744.1:c.720+1634G>A, rs58886669
C > T
SNP
No VIP available No Clinical Annotations available VA
rs3778151 NC_000006.11:g.154393680T>C, NC_000006.12:g.154072545T>C, NG_021208.1:g.67045T>C, NM_000914.4:c.291-17281T>C, NM_001008503.2:c.291-17281T>C, NM_001008504.3:c.291-17281T>C, NM_001008505.2:c.291-17281T>C, NM_001145279.3:c.570-17281T>C, NM_001145280.3:c.-10-17281T>C, NM_001145281.2:c.48-17281T>C, NM_001145282.2:c.291-17281T>C, NM_001145283.2:c.291-17281T>C, NM_001145284.3:c.291-17281T>C, NM_001145285.2:c.291-17281T>C, NM_001145286.2:c.291-17281T>C, NM_001285522.1:c.290+32711T>C, NM_001285523.1:c.291-17281T>C, NM_001285524.1:c.570-17281T>C, NR_104348.1:n.425-17281T>C, NR_104349.1:n.425-17281T>C, NR_104350.1:n.425-18407T>C, NR_104351.1:n.425-17281T>C, XM_005267002.1:c.477-17281T>C, XM_006715497.2:c.*5-970T>C, XM_011535849.1:c.570-17281T>C, XR_245534.1:n.477-17281T>C, XR_245535.1:n.477-17281T>C, XR_245536.1:n.477-17281T>C, XR_245537.1:n.477-18407T>C, rs17181122
T > C
SNP
No VIP available CA VA
rs510769 NC_000006.11:g.154362019C>T, NC_000006.12:g.154040884C>T, NG_021208.1:g.35384C>T, NM_000914.4:c.290+1050C>T, NM_001008503.2:c.290+1050C>T, NM_001008504.3:c.290+1050C>T, NM_001008505.2:c.290+1050C>T, NM_001145279.3:c.569+1050C>T, NM_001145280.3:c.-11+29866C>T, NM_001145281.2:c.47+30325C>T, NM_001145282.2:c.290+1050C>T, NM_001145283.2:c.290+1050C>T, NM_001145284.3:c.290+1050C>T, NM_001145285.2:c.290+1050C>T, NM_001145286.2:c.290+1050C>T, NM_001285522.1:c.290+1050C>T, NM_001285523.1:c.290+1050C>T, NM_001285524.1:c.569+1050C>T, NR_104348.1:n.424+1050C>T, NR_104349.1:n.424+1050C>T, NR_104350.1:n.424+1050C>T, NR_104351.1:n.424+1050C>T, XM_005267002.1:c.476+1050C>T, XM_006715497.2:c.476+1050C>T, XM_011535849.1:c.569+1050C>T, XR_245534.1:n.476+1050C>T, XR_245535.1:n.476+1050C>T, XR_245536.1:n.476+1050C>T, XR_245537.1:n.476+1050C>T, rs17174649, rs3778144, rs386597658, rs52810976, rs61175746
C > T
SNP
No VIP available CA VA
rs544093 NC_000006.11:g.154457493G>T, NC_000006.12:g.154136358G>T, NG_021208.1:g.130858G>T, NM_001008503.2:c.1164+44886G>T, rs59335321
G > T
SNP
No VIP available CA VA
rs558025 NC_000006.11:g.154441965A>G, NC_000006.12:g.154120830A>G, NG_021208.1:g.115330A>G, NM_000914.4:c.*2109A>G, NM_001008503.2:c.1164+29358A>G, NM_001145279.3:c.*2109A>G, NM_001145280.3:c.*2109A>G, NM_001145281.2:c.*2109A>G, NM_001145287.2:c.*2109A>G, NM_001285522.1:c.*2144A>G, NM_001285524.1:c.*2109A>G, NM_001285526.1:c.*2109A>G, NR_104348.1:n.3555A>G, NR_104350.1:n.3093A>G, XM_011535849.1:c.*293-191A>G, XM_011535859.1:c.*2109A>G, XM_011535860.1:c.*2109A>G, XM_011535861.1:c.*2109A>G, rs17181380, rs17276643, rs61090595
A > -
A > G
SNP
No VIP available CA VA
rs9384179 NC_000006.11:g.154421057G>A, NC_000006.12:g.154099922G>A, NG_021208.1:g.94422G>A, NM_000914.4:c.1164+8450G>A, NM_001008503.2:c.1164+8450G>A, NM_001145279.3:c.1443+8450G>A, NM_001145280.3:c.864+8450G>A, NM_001145281.2:c.921+8450G>A, NM_001145282.2:c.1164+8450G>A, NM_001145283.2:c.1165-8094G>A, NM_001145284.3:c.1165-7826G>A, NM_001145285.2:c.1165-7694G>A, NM_001145286.2:c.1165-7543G>A, NM_001145287.2:c.864+8450G>A, NM_001285522.1:c.291-18761G>A, NM_001285524.1:c.1443+8450G>A, NM_001285526.1:c.864+8450G>A, NR_104348.1:n.1407+5604G>A, NR_104349.1:n.1407+5604G>A, NR_104350.1:n.945+8450G>A, NR_104351.1:n.1407+5604G>A, XM_005267003.1:c.864+8450G>A, XM_011535849.1:c.1443+8450G>A, XM_011535859.1:c.864+8450G>A, XM_011535860.1:c.864+8450G>A, XM_011535861.1:c.864+8450G>A, XR_245534.1:n.1459+5604G>A, XR_245535.1:n.1459+5604G>A, XR_245536.1:n.1459+5604G>A, XR_245537.1:n.997+8450G>A
G > A
SNP
No VIP available CA VA
rs9479757 NC_000006.11:g.154411344G>A, NC_000006.12:g.154090209G>A, NG_021208.1:g.84709G>A, NM_000914.4:c.643+31G>A, NM_001008503.2:c.643+31G>A, NM_001008504.3:c.643+31G>A, NM_001008505.2:c.643+31G>A, NM_001145279.3:c.922+31G>A, NM_001145280.3:c.343+31G>A, NM_001145281.2:c.400+31G>A, NM_001145282.2:c.643+31G>A, NM_001145283.2:c.643+31G>A, NM_001145284.3:c.643+31G>A, NM_001145285.2:c.643+31G>A, NM_001145286.2:c.643+31G>A, NM_001145287.2:c.343+31G>A, NM_001285522.1:c.291-28474G>A, NM_001285523.1:c.643+31G>A, NM_001285524.1:c.922+31G>A, NM_001285526.1:c.343+31G>A, NM_001285527.1:c.343+31G>A, NM_001285528.1:c.343+31G>A, NR_104348.1:n.777+31G>A, NR_104349.1:n.777+31G>A, NR_104350.1:n.425-743G>A, NR_104351.1:n.777+31G>A, XM_005267002.1:c.829+31G>A, XM_005267003.1:c.343+31G>A, XM_011535849.1:c.922+31G>A, XM_011535850.1:c.436+31G>A, XM_011535851.1:c.343+31G>A, XM_011535852.1:c.343+31G>A, XM_011535853.1:c.343+31G>A, XM_011535854.1:c.343+31G>A, XM_011535855.1:c.343+31G>A, XM_011535856.1:c.343+31G>A, XM_011535857.1:c.343+31G>A, XM_011535858.1:c.343+31G>A, XM_011535859.1:c.343+31G>A, XM_011535860.1:c.343+31G>A, XM_011535861.1:c.343+31G>A, XM_011535862.1:c.343+31G>A, XR_245534.1:n.829+31G>A, XR_245535.1:n.829+31G>A, XR_245536.1:n.829+31G>A, XR_245537.1:n.477-743G>A, rs17174808, rs60522300
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  None
Alternate Symbols:  MOR1
PharmGKB Accession Id: PA31945

Details

Cytogenetic Location: chr6 : q25.2 - q25.2
GP mRNA Boundary: chr6 : 154331631 - 154568001
GP Gene Boundary: chr6 : 154321631 - 154571001
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
abacavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
acamprosate
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
acetaminophen
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
alfentanil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amitriptyline
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
amphetamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
anastrozole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aripiprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
arsenic trioxide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
atomoxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
atorvastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
boceprevir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
bromocriptine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
buprenorphine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
bupropion
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
butorphanol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
carbamazepine
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
carboplatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
carisoprodol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
carvedilol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
celecoxib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cetuximab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cevimeline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chloroquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
citalopram
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clobazam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clomipramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clopidogrel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clozapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
codeine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
crizotinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cyclosporine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dapsone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dasatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
desipramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dextromethorphan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
diazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
diphenoxylate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
disulfiram
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
docetaxel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dopamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
doxepin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
efavirenz
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
entacapone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
erlotinib
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ethanol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
exemestane
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
fentanyl
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluoxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flurbiprofen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fulvestrant
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
gefitinib
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
heroin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydralazine
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
hydrocodone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydromorphone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
iloperidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
imatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
imipramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
indacaterol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
irinotecan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
isoniazid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ivacaftor
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lapatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lenalidomide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
letrozole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
levodopa
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
levorphanol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
maraviroc
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
meperidine
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
methadone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
methamphetamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
metoprolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
modafinil
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
morphine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
morphine-6-glucuronide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mycophenolate mofetil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nalbuphine
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
naloxone
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
naltrexone
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
nicotine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nilotinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nortriptyline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
omeprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
oxycodone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oxymorphone
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
paclitaxel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
panitumumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pantoprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
paroxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
peginterferon alfa-2b
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pentazocine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
perphenazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pertuzumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
phenytoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pimozide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pramipexole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
prasugrel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pravastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
primaquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
propafenone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
propoxyphene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
propranolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
quinidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rasagiline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
risperidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ropinirole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rotigotine transdermal patch
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
selegiline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sirolimus
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sufentanil
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
sumatriptan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tacrolimus
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tamoxifen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
telaprevir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
terbinafine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
thioridazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ticagrelor
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tolcapone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
toremifene
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
tramadol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trastuzumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tretinoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trimipramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tripelennamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
valproic acid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
varenicline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vemurafenib
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
venlafaxine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
voriconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
warfarin

Curated Information ?

Publications related to OPRM1: 77

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Emergent biomarker derived from next-generation sequencing to identify pain patients requiring uncommonly high opioid doses. The pharmacogenomics journal. 2016. Kringel D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The AC/AG Diplotype for the 118A>G and IVS2 + 691G>C Polymorphisms of OPRM1 Gene is Associated with Sleep Quality Among Opioid-Dependent Patients on Methadone Maintenance Therapy. Pain and therapy. 2016. Zahari Zalina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The pharmacogenetics of opioid therapy in the management of postpartum pain: a systematic review. Pharmacogenomics. 2016. Baber Marta, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The pharmacogenetics of codeine pain relief in the postpartum period. The pharmacogenomics journal. 2015. Baber M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial. JAMA psychiatry. 2015. Oslin David W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of opioid response. Clinical pharmacology and therapeutics. 2015. Somogyi A A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients. Pharmacogenetics and genomics. 2015. Foulds James A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. British journal of clinical pharmacology. 2014. Mouly S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Subjective response as a consideration in the pharmacogenetics of alcoholism treatment. Pharmacogenomics. 2015. Roche Daniel Jo, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Prediction formulas for individual opioid analgesic requirements based on genetic polymorphism analyses. PloS one. 2015. Yoshida Kaori, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache. European journal of clinical pharmacology. 2014. Cargnin Sarah, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis. Pharmacogenomics. 2014. Jonas Daniel E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of OPRM1 A118G variant with risk of morphine-induced respiratory depression following spine fusion in adolescents. The pharmacogenomics journal. 2014. Chidambaran V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Associations of OPRM1 A118G and alcohol sensitivity with intravenous alcohol self-administration in young adults. Addiction biology. 2014. Hendershot Christian S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype. Pharmacogenomics. 2014. Matic Maja, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Parkinson's disease pharmacogenomics: new findings and perspectives. Pharmacogenomics. 2014. Schumacher-Schuh Artur F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: tramadol pathway. Pharmacogenetics and genomics. 2014. Gong Li, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A logistic equation to determine the validity of tramadol from related gene polymorphisms and psychological factors. Pharmacogenomics. 2014. Zhao Qin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013. McWhinney-Glass Sarah, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder. Human psychopharmacology. 2013. Cooper Alissa J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA : the journal of the American Medical Association. 2013. Wachman Elisha M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. Pharmacogenomics. 2013. Levran Orna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. Pharmacogenomics. 2013. Haerian Batoul Sadat, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone. Pain physician. 2013. Boswell Mark V, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study. PloS one. 2013. Beer Beate, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
μ-Opioid receptor availability in the amygdala is associated with smoking for negative affect relief. Psychopharmacology. 2012. Falcone Mary, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clinical pharmacology and therapeutics. 2012. Sistonen J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy. Cancer. 2012. Liu Yu-Chang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of alcoholism: a clinical neuroscience perspective. Pharmacogenomics. 2012. Ray Lara A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenetics and genomics. 2011. Coller Janet K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011. Hung Chin-Chuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of Naltrexone in Asian Americans: A Randomized Placebo-Controlled Laboratory Study. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2011. Ray Lara A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. Regulatory toxicology and pharmacology : RTP. 2011. Volpe Donna A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clinical pharmacology and therapeutics. 2011. Sadee W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
OPRM1 gene variants modulate amphetamine-induced euphoria in humans. Genes, brain, and behavior. 2011. Dlugos A M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Lack of Association of OPRM1 and ABCB1 Single-Nucleotide Polymorphisms to Oxycodone Response in Postoperative Pain. Journal of clinical pharmacology. 2011. Zwisler Stine T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia. Minerva anestesiologica. 2011. Zhang W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction. Clinical pharmacology and therapeutics. 2010. Ho M K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Adverse events in analgesic treatment with tramadol associated with CYP2D6 extensive-metaboliser and OPRM1 high-expression variants. Annals of the rheumatic diseases. 2010. Kim Eunjin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clinical pharmacology and therapeutics. 2010. Bunten H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mu-opioid receptors are not necessary for nortriptyline treatment of neuropathic allodynia. European journal of pain (London, England). 2010. Bohren Yohann, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundamental & clinical pharmacology. 2010. Zwisler Stine T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug and alcohol dependence. 2010. Mague Stephen D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of Mu-Opioid Receptor Variants and Response to Citalopram Treatment in Major Depressive Disorder. The American journal of psychiatry. 2010. Garriock Holly A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. Journal of neurochemistry. 2010. Deb Ishani, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. Pain. 2009. Fukuda Kenichi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic modulation of the pharmacological treatment of pain. Pharmacology & therapeutics. 2009. Lötsch Jörn, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Mu-opioid receptor (A118G) single-nucleotide polymorphism affects alfentanil requirements for extracorporeal shock wave lithotripsy: a pharmacokinetic-pharmacodynamic study. British journal of anaesthesia. 2009. Ginosar Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The G allele of SNP E1/A118G at the mu-opioid receptor gene locus shows genomic evidence of recent positive selection. Pharmacogenomics. 2009. Pang Grace S Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenetics and genomics. 2009. Lötsch Jörn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional characterization of human variants of the mu-opioid receptor gene. Proceedings of the National Academy of Sciences of the United States of America. 2009. Ravindranathan Ajay, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics. 2008. Hayashida Masakazu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain. 2008. Landau Ruth, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics. 2008. Madadi Parvaz, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The pharmacogenetics of morphine-induced analgesia: a case report. Journal of pain and symptom management. 2008. Bianchi Mauro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics. 2008. Rollason Victoria, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clinical pharmacology and therapeutics. 2008. Campa D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of morphine: Potential implications in sickle cell disease. American journal of hematology. 2008. Darbari Deepika S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Archives of general psychiatry. 2008. Anton Raymond F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation. Pharmacogenetics and genomics. 2007. Hernandez-Avila Carlos A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of the mu-opioid receptor gene with smoking cessation. The pharmacogenomics journal. 2007. Munafò M R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007. Reyes-Gibby Cielito C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Overview of the pharmacogenomics of cigarette smoking. The pharmacogenomics journal. 2007. Ho M K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. Archives of general psychiatry. 2007. Barr Christina S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clinical pharmacology and therapeutics. 2006. Lötsch Jörn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms. The pharmacogenomics journal. 2006. Ide S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. The pharmacogenomics journal. 2006. Lötsch J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2005. Bart Gavin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcoholism, clinical and experimental research. 2004. Ray Lara A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. The pharmacogenomics journal. 2004. Lerman C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2003. Oslin David W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2003. Hernandez-Avila Carlos A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2002. Wand Gary S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics. 2002. Lötsch Jörn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proceedings of the National Academy of Sciences of the United States of America. 1998. Bond C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life sciences. 1995. Mignat C, et al. PubMed